Market Snapshot
S&P Futures
3,814.5
Dow Futures
30,961
Nasdaq Futures
11,557.75
bluebird bio, Inc. (BLUE) stock rallied over 3.38% intraday to trade at $4.28 a share on NASDAQ. The stock opened with a loss of -4.04% at $4.14 and touched an intraday high of $4.33, rising 3.38% against the last close of $4.14. The stock went to a low of $4.07 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-07-01 | $4.14 | $4.33 | $4.07 | $4.28 | 3,995,500 |
2022-06-30 | $4.46 | $4.54 | $4.12 | $4.14 | 6,418,700 |
2022-06-29 | $4.01 | $4.66 | $3.89 | $4.58 | 12,419,200 |
2022-06-28 | $4.23 | $4.23 | $3.9 | $4.04 | 7,730,000 |
2022-06-27 | $4.39 | $4.4 | $4.07 | $4.29 | 5,323,800 |
2022-06-24 | $4.25 | $4.49 | $4.02 | $4.4 | 7,703,200 |
2022-06-23 | $4 | $4.29 | $3.8 | $4.28 | 11,094,500 |
2022-06-22 | $4.03 | $4.72 | $3.91 | $4.46 | 15,190,100 |
2022-06-21 | $3.66 | $4.4 | $3.55 | $4.16 | 20,914,900 |
2022-06-17 | $3.24 | $4.29 | $3.16 | $3.56 | 63,659,600 |
Employees-
Beta1.35
Sales or Revenue3.66 Million
5Y Sales Change-9.90%
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
bluebird bio, Inc. (NASDAQ: BLUE) stock price is $4.28 as of the last check on Friday, July 1. During the trading session, BLUE stock reached the peak price of $4.33 while $4.07 was the lowest point it dropped to.
The NASDAQ listed BLUE is part of Biotechnology industry that operates in the broader Health Care sector. bluebird bio, Inc. , a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases.
Mr. Nick Leschly
Pres & Director
Mr. William D. Baird III
Principal Financial & Accounting Officer
Mr. Andrew Obenshain
CEO & Director
Ms. Gina R. Consylman CPA
Chief Financial Officer
BLUE stock traded closed the last session at $4.28, which is $0.14 or 3.38% lower than its previous close of $4.14. BLUE's current trading price is 49.39% lower than its 52-week high of $21.16 where as its distance from 52-week low of 2.87% is -79.77%.
Number of BLUE employees currently stands at -. BLUE operates from 60 Binney Street, Cambridge, MA 02142, United States.
Official Webiste of $BLUE is: https://www.bluebirdbio.com
BLUE could be contacted at BLUE operates from 60 Binney Street, Cambridge, MA 02142, United States, or at phone #339 499 9300 and can also be accessed through its website.
BLUE stock volume for the day was 3,986,981 shares while in the previous session number of BLUE shares traded was 3,995,500 . The average number of BLUE shares traded daily for last 3 months was 6.11 Million.
The percentage change in BLUE stock occurred in the recent session was 3.38% while the dollar amount for the price change in BLUE stock was $0.14.
In the recent session, the day high for BLUE stock was $4.33 while the low for BLUE stock touched on the day was $4.07.
The market value of BLUE currently stands at 295.79 Million with its latest stock price at $4.28 and 73.69 Million of its shares outstanding.